Umair Ashraf, MD
Pulmonary Disease · Houston, TXNPI 1487095089
Payments from drug & device makers
Across 282 payments — averaging $50.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3K
- Covidien LP$2K
- Medical Device Business Services, Inc.$1K
- Genentech USA, Inc.$1K
- Boehringer Ingelheim$1K
- AstraZeneca$759
- plus $5K from 32 others
What the payments were for
- Travel & lodging$3,72134%
- Food & beverage$7,22566%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $3,420 |
| Covidien LP | 3 | $1,893 |
| Medical Device Business Services, Inc. | 5 | $1,244 |
| Genentech USA, Inc. | 5 | $1,147 |
| Boehringer Ingelheim | 34 | $1,041 |
| AstraZeneca(2 entities) | 29 | $759 |
| United Therapeutics Corporation | 32 | $693 |
| GSK | 30 | $600 |
| Actelion Pharmaceuticals US, Inc. | 22 | $585 |
| Insmed, Inc. | 16 | $415 |
| Baxter Healthcare | 12 | $289 |
| Shionogi Inc | 11 | $268 |
| Grifols USA, LLC | 9 | $239 |
| Mylan Specialty L.p. | 7 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $181 |
| AbbVie | 10 | $174 |
| ANI Pharmaceuticals, Inc. | 3 | $166 |
| Regeneron Healthcare Solutions, Inc. | 6 | $152 |
| Body Vision Medical Inc. | 1 | $122 |
| Astellas Pharma US Inc | 4 | $111 |
| Bayer | 5 | $96 |
| Sanofi | 4 | $93 |
| Advanced Respiratory, Inc | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Merck | 2 | $38 |
| Johnson & Johnson | 1 | $34 |
| Philips North America LLC | 2 | $30 |
| Resmed Corp | 2 | $28 |
| Pfizer | 2 | $27 |
| 3b Medical, Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $26 |
| Inogen, Inc. | 2 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Sandoz | 1 | $22 |
| Optinose US, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- superDimension$1,893
- NA$1,190
- Arikayce$127
- Strensiq$125
- PURIFIED CORTROPHIN GEL$124
- LungVision$122
- IMFINZI$116
- OFEV$107
- TYVASO$100
How this compares
$14,366 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $209,917 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $86,550 |
| Spiriva RespimatTiotropium Bromide | 21 | $17,088 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $15,750 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $11,862 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $10,252 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $8,721 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $8,418 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,981 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,939 |
| Roflumilast | 15 | $3,379 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $2,769 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,921 |
| Ipratropium Bromide | 13 | $890 |
| Montelukast Sodium | 44 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,041 | $235,72653 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $600 | $121,021179 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $759 | $19,73232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.